NCT06433908View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

October 17, 2024

Study Completion Date

October 22, 2024

Conditions
AsthmaHealthy Participants
Interventions
DRUG

Salbutamol HFA-152a

100 µg (ex-valve), given at 20-second intervals.

DRUG

Salbutamol HFA-134a

100 µg (ex-valve), given at 20-second intervals.

Trial Locations (1)

9728

GSK Investigational Site, Groningen

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06433908 - A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive | Biotech Hunter | Biotech Hunter